MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events:

MST Financial Lifesciences & Biotech FourmWednesday, November 24^th at 5:20 p.m. PST (U.S.) / Thursday, November 25^th at 12.20 pm AEST A link to the live and recorded webcast will be available on the Alterity website.

Benchmark Company Discovery One-on-One Investor ConferenceThursday, December 2^nd (U.S.) /  Friday, December 3^rd (Australia)

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.^[1]

Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contact: Investor Relations

View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-two-upcoming-investor-conferences-301429828.html^[2]

References

1. ^{^} www.alteritytherapeutics.com. (www.alteritytherapeutics.com)
2. ^{^} https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-two-upcoming-investor-conferences-301429828.html (www.prnewswire.com)